19 June 2013 - 19 June 2013 - US biopharmaceutical company PhaseBio announced on Tuesday that it has completed a Phase I clinical trial of Vasomera (PB1046) for cardiopulmonary diseases treatment and that it has initiated a second Phase I study.

The second trial will enrol up to 32 patients and is expected to be completed in the third quarter of this year.

Vasomera is an investigational, once-weekly, vasoactive intestinal peptide receptor 2 (VPAC2) agonist. The Phase I trial demonstrated the tolerability, safety, pharmacokinetic and pharmacodynamic response of single ascending subcutaneous doses of the drug in 40 patients. The results revealed pharmacodynamic activity that was supportive of a once-weekly regimen which could allow for chronic use in home setting.

Based on those results, PhaseBio initiated a second Phase I clinical trial to assess the tolerability, safety, pharmacokinetic and pharmacodynamic response of single ascending dosing regimen of short-term intravenous (IV)-infused Vasomera. IV administration would enable acute hospital setting usage and aims to preserve and improve hemodynamic function in heart failure and reduce the possibility of re-hospitalisation.